Surgery Partners, Inc. (SGRY): Results of Operations and Financial Condition
Surgery Partners, Inc. (SGRY) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991q22026earningsre.htm EX-99.1 Document Exhibit 99.1 SURGERY PARTNERS, INC. ANNOUNCES SECOND QUARTER 2026 RESULTS REAFFIRMS FULL YEAR 2026 GUIDANCE BRENTWOOD, Tenn., August 10, 2026 (GLOBE NEWSWIRE) - Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or t
How this was made
The 30-second read
Why it matters
Traders can update expectations for 2026 revenue and Adjusted EBITDA based on reaffirmed targets, while monitoring the transaction’s approval and closing timeline as a key driver of deleveraging and cash conversion.
Market read
Q2 results show modest revenue growth but lower Adjusted EBITDA and weaker operating cash flow, while management reaffirmed 2026 guidance and tied portfolio optimization to the pending Idaho Falls transaction.
What to watch
Closing conditions for the Idaho Falls transaction (physician members and governing board approvals) could delay deleveraging benefits, and the filing notes potential adverse effects of transaction pendency on trading and business relationships.
Background
This SEC 8-K includes Exhibit 99.1 with Surgery Partners’ Q2 2026 results and a reaffirmation of full-year 2026 guidance, plus commentary on a pending Idaho Falls divestiture.
Ticker impact
Surgery Partners reported Q2 2026 revenue of $848.9M, reaffirmed 2026 guidance, and discussed the pending Idaho Falls divestiture’s impact on cash conversion and deleveraging.
Likely modest, guidance-reaffirmation-driven support, with volatility tied to closing conditions for the Idaho Falls transaction and operating cash flow softness.
The filing provides fresh quarterly datapoints (revenue, same-facility metrics, Adjusted EBITDA, operating cash flow) and reiterates 2026 targets, but the divestiture is still pending and subject to approvals, limiting certainty on timing and magnitude of deleveraging.
Market effects
Reinforces the short-stay ASC operator narrative that portfolio optimization and cash conversion are key levers, potentially influencing sentiment across similarly leveraged healthcare facility operators.
Limited, since the disclosed transaction is Idaho Falls-specific and the guidance is company-wide.
Low, as this is a US-listed company earnings and divestiture update with no cross-border operational disclosure.
Counterpoint
The reaffirmed guidance may mask underlying margin pressure, given Adjusted EBITDA declined year over year and operating cash flow fell versus the prior-year quarter.
Key entities
- public_companySurgery Partners, Inc.
NASDAQ-listed short-stay surgical facility owner and operator reporting Q2 2026 results and reaffirming 2026 guidance.
- transactionIdaho Falls transaction
Pending divestiture referenced as subject to physician and governing board approvals, expected to strengthen financial position via improved cash conversion and deleveraging.
